Shikonin demonstrates synergistic effects when combined with the PI3K-Akt-mTOR inhibitor BEZ235, significantly reducing the viability of chemotherapy-resistant lung cancer cells (Huang et al., 2024). Here, AKT1 is linked to lung cancer.